Magazine Article | February 1, 2021

Thrust Into A New Fundraising Norm

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

By the time Randy Schatzman, Ph.D., was the guest on The Business of Biotech podcast, his company, Bolt Biotherapeutics, already had closed a $93 million Series C round of financing in the early months of the COVID pandemic. The CEO had joined Bolt, which focuses on immuno-oncology drug discovery and development, only a year prior.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader